Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PTN Stock Forecast 2026-2027
$21.85
Current Price
$38.72M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PTN Price Targets
+174.6%
To High Target of $60.00
+142.6%
To Median Target of $53.00
+128.8%
To Low Target of $50.00
PTN Price Momentum
+0.3%
1 Week Change
+1.9%
1 Month Change
+108.1%
1 Year Change
+42.1%
Year-to-Date Change
-29.5%
From 52W High of $31.00
+992.5%
From 52W Low of $2.00
📊 TOP ANALYST CALLS
Did PTN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Palatin is one of their latest high-conviction picks.
Latest PTN Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, PTN has a bullish consensus with a median price target of $53.00 (ranging from $50.00 to $60.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $21.85, the median forecast implies a 142.6% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PTN Analyst Ratings
3
Buy
0
Hold
0
Sell
PTN Price Target Range
Low
$50.00
Average
$53.00
High
$60.00
Current: $21.85
Latest PTN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PTN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 12, 2025 | Laidlaw & Co. | Buy | Initiates | $N/A | |
| Feb 13, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 7, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 19, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 25, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 4, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 31, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 24, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 20, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 12, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 8, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 2, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 28, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 10, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 8, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 7, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 30, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 9, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Palatin Technologies, Inc. (PTN) Competitors
The following stocks are similar to Palatin based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Palatin Technologies, Inc. (PTN) Financial Data
Palatin Technologies, Inc. has a market capitalization of $38.72M with a P/E ratio of -0.7x. The company generates $8.96M in trailing twelve-month revenue with a -107.4% profit margin.
Revenue growth is -98.7% quarter-over-quarter, while maintaining an operating margin of -6,315.8% and return on equity of -378.7%.
Valuation Metrics
Market Cap
$38.72M
Enterprise Value
$24.99M
P/E Ratio
-0.7x
PEG Ratio
0.0x
Price/Sales
4.3x
Growth & Margins
Revenue Growth (YoY)
-98.7%
Gross Margin
N/A
Operating Margin
-6,315.8%
Net Margin
-107.4%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+37.4%
Current Ratio
2.8x
Debt/Equity
3.0x
ROE
-378.7%
ROA
-70.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Palatin Technologies, Inc. (PTN) Business Model
About Palatin Technologies, Inc.
What They Do
Biopharmaceutical company focused on melanocortin therapeutics.
Business Model
Palatin Technologies generates revenue through the development and commercialization of innovative therapeutic agents targeting the melanocortin receptor system. Their business model includes advancing a diverse pipeline of peptide and small molecule agonists, seeking FDA approvals, and engaging in strategic collaborations with other pharmaceutical companies to enhance their research and development efforts.
Additional Information
The company has made significant strides in treating unmet medical needs, particularly in ocular and inflammatory conditions, and has established a notable presence in the biopharmaceutical industry with products like Vyleesi. Collaborations with industry leaders, such as Boehringer Ingelheim, indicate a strong focus on innovation and expanding its therapeutic reach, particularly in retinal diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
29
CEO
Dr. Carl Spana Ph.D.
Country
United States
IPO Year
1997
Website
palatin.comPalatin Technologies, Inc. (PTN) Latest News & Analysis
Latest News
Quick Summary
Palatin Technologies, Inc. (PTN) held its Q2 2026 earnings call, discussing financial performance and updates on business operations. Further details are available in the transcript.
Why It Matters
Palatin Technologies' Q2 2026 earnings reveal financial performance and growth prospects, impacting stock valuation and investor confidence in future potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
2 months ago
Quick Summary
Palatin Technologies is advancing MC4R-based obesity therapies, with IND filings for two drugs planned in 2026. They also secured $3.8M from sublicensing and completed an $18.2M public offering.
Why It Matters
Advancements in MC4R-based obesity therapies could lead to significant market opportunities. Successful clinical trials and financing indicate potential for growth, impacting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Palatin Technologies, Inc. (OTC:PTN) will hold its Q1 2026 earnings call on November 13, 2025, at 11:00 AM EST, featuring CEO Carl Spana and CFO Steve Wills.
Why It Matters
Palatin's Q1 earnings call indicates financial performance and strategic direction, impacting stock valuation and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
5 months ago
Quick Summary
Palatin Technologies reports advancements in its obesity pipeline, collaborations with Boehringer Ingelheim, a successful $18.2M public offering, and regained NYSE compliance. Trading resumed under "PTN".
Why It Matters
Palatin Technologies' advancements in obesity therapies and collaborations, alongside a strengthened balance sheet and stock compliance, signal growth potential and reduced risk, attracting investor interest.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Palatin Technologies resumed trading on NYSE under "PTN" on November 12, 2025, after closing a public offering of 2,795,384 shares, including 364,615 additional shares purchased by underwriters.
Why It Matters
Resumption of trading and a successful public offering indicate liquidity and investor confidence in Palatin, potentially influencing stock price and market sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Palatin Technologies (OTC PINK: PTNT) will hold a teleconference and webcast today at 11 AM EST to discuss significant progress in its obesity and ocular programs and release Q3 fiscal results.
Why It Matters
Palatin Technologies' advancements in obesity and ocular treatments could signal potential growth and new revenue streams, impacting stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PTN Stock
What is Palatin Technologies, Inc.'s (PTN) stock forecast for 2026?
Based on our analysis of 1 Wall Street analysts, Palatin Technologies, Inc. (PTN) has a median price target of $53.00. The highest price target is $60.00 and the lowest is $50.00.
Is PTN stock a good investment in 2026?
According to current analyst ratings, PTN has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $21.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PTN stock?
Wall Street analysts predict PTN stock could reach $53.00 in the next 12 months. This represents a 142.6% increase from the current price of $21.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Palatin Technologies, Inc.'s business model?
Palatin Technologies generates revenue through the development and commercialization of innovative therapeutic agents targeting the melanocortin receptor system. Their business model includes advancing a diverse pipeline of peptide and small molecule agonists, seeking FDA approvals, and engaging in strategic collaborations with other pharmaceutical companies to enhance their research and development efforts.
What is the highest forecasted price for PTN Palatin Technologies, Inc.?
The highest price target for PTN is $60.00 from at , which represents a 174.6% increase from the current price of $21.85.
What is the lowest forecasted price for PTN Palatin Technologies, Inc.?
The lowest price target for PTN is $50.00 from at , which represents a 128.8% increase from the current price of $21.85.
What is the overall PTN consensus from analysts for Palatin Technologies, Inc.?
The overall analyst consensus for PTN is bullish. Out of 1 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $53.00.
How accurate are PTN stock price projections?
Stock price projections, including those for Palatin Technologies, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 2:10 PM UTC